6IVP
 
 | | Crystal structure of a membrane protein P262A | | 分子名称: | CHLORIDE ION, ZINC ION, bestrophin | | 著者 | Kittredge, A, Fukuda, F, Zhang, Y, Yang, T. | | 登録日 | 2018-12-04 | | 公開日 | 2019-11-06 | | 最終更新日 | 2024-05-29 | | 実験手法 | X-RAY DIFFRACTION (3.8 Å) | | 主引用文献 | Dual Ca2+-dependent gates in human Bestrophin1 underlie disease-causing mechanisms of gain-of-function mutations.
Commun Biol, 2, 2019
|
|
6IVM
 | | Crystal structure of a membrane protein P143A | | 分子名称: | 1,2-ETHANEDIOL, ACETIC ACID, CHLORIDE ION, ... | | 著者 | Kittredge, A, Fukuda, F, Zhang, Y, Yang, T. | | 登録日 | 2018-12-04 | | 公開日 | 2019-11-06 | | 最終更新日 | 2024-05-29 | | 実験手法 | X-RAY DIFFRACTION (2.95 Å) | | 主引用文献 | Dual Ca2+-dependent gates in human Bestrophin1 underlie disease-causing mechanisms of gain-of-function mutations.
Commun Biol, 2, 2019
|
|
6IVO
 | | Crystal structure of a membrane protein P208A | | 分子名称: | 1,2-ETHANEDIOL, ACETIC ACID, CHLORIDE ION, ... | | 著者 | Kittredge, A, Fukuda, F, Zhang, Y, Yang, T. | | 登録日 | 2018-12-04 | | 公開日 | 2019-11-06 | | 最終更新日 | 2024-05-29 | | 実験手法 | X-RAY DIFFRACTION (2.45 Å) | | 主引用文献 | Dual Ca2+-dependent gates in human Bestrophin1 underlie disease-causing mechanisms of gain-of-function mutations.
Commun Biol, 2, 2019
|
|
6IV4
 | |
6IVR
 | | Crystal structure of a membrane protein W16A | | 分子名称: | 1,2-ETHANEDIOL, ACETIC ACID, CHLORIDE ION, ... | | 著者 | Kittredge, A, Fukuda, F, Zhang, Y, Yang, T. | | 登録日 | 2018-12-04 | | 公開日 | 2019-11-06 | | 最終更新日 | 2024-05-29 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | Dual Ca2+-dependent gates in human Bestrophin1 underlie disease-causing mechanisms of gain-of-function mutations.
Commun Biol, 2, 2019
|
|
6IV1
 | |
5X87
 | |
6XKQ
 | | Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-250 | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CV07-250 Heavy Chain, CV07-250 Light Chain, ... | | 著者 | Yuan, M, Liu, H, Zhu, X, Wu, N.C, Wilson, I.A. | | 登録日 | 2020-06-26 | | 公開日 | 2020-10-14 | | 最終更新日 | 2023-10-18 | | 実験手法 | X-RAY DIFFRACTION (2.55 Å) | | 主引用文献 | A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
Cell, 183, 2020
|
|
6XKP
 | | Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-270 | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CV07-270 Heavy Chain, CV07-270 Light Chain, ... | | 著者 | Liu, H, Yuan, M, Zhu, X, Wu, N.C, Wilson, I.A. | | 登録日 | 2020-06-26 | | 公開日 | 2020-10-14 | | 最終更新日 | 2023-10-18 | | 実験手法 | X-RAY DIFFRACTION (2.72 Å) | | 主引用文献 | A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
Cell, 183, 2020
|
|
7S5Q
 | |
7S5P
 | |
7S5R
 | |
7PUS
 | | ERK5 in complex with Pyrrole Carboxamide scaffold | | 分子名称: | 4-[3,6-bis(chloranyl)-2-fluoranyl-phenyl]carbonyl-~{N}-(1-methylpyrazol-4-yl)-1~{H}-pyrrole-2-carboxamide, Mitogen-activated protein kinase 7 | | 著者 | Tucker, J.A, Martin, M.P, Endicott, J.A, Noble, M.E.N. | | 登録日 | 2021-09-30 | | 公開日 | 2022-05-11 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (2.59 Å) | | 主引用文献 | Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor.
J.Med.Chem., 65, 2022
|
|
5LRQ
 | | BRD4 in complex with ERK5 inhibitor XMD8-92 | | 分子名称: | 2-{[2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino}-5,11-dimethyl-5,11-dihydro-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one, Bromodomain-containing protein 4 | | 著者 | Martin, M.P, Noble, M.E.M. | | 登録日 | 2016-08-19 | | 公開日 | 2017-08-30 | | 最終更新日 | 2024-01-17 | | 実験手法 | X-RAY DIFFRACTION (1.7 Å) | | 主引用文献 | Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38 alpha and BRD4.
Eur.J.Med.Chem., 178, 2019
|
|
3FT5
 | | Structure of HSP90 bound with a novel fragment | | 分子名称: | 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine, Heat shock protein HSP 90-alpha | | 著者 | Barker, J.B, Mather, O, Cheng, R.K.Y, Palan, S, Felicetti, B. | | 登録日 | 2009-01-12 | | 公開日 | 2009-05-05 | | 最終更新日 | 2024-02-21 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | Fragment-based Identification of Hsp90 Inhibitors.
Chemmedchem, 4, 2009
|
|
3FT8
 | | Structure of HSP90 bound with a noval fragment. | | 分子名称: | (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime, Heat shock protein HSP 90-alpha | | 著者 | Barker, J.B, Cheng, R.K.Y, Palan, S, Felicetti, B. | | 登録日 | 2009-01-12 | | 公開日 | 2009-06-30 | | 最終更新日 | 2024-02-21 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | Fragment-based identification of Hsp90 inhibitors.
Chemmedchem, 4, 2009
|
|
5JZD
 | | A re-refinement of the isochorismate synthase EntC | | 分子名称: | (5S,6S)-5-[(1-carboxyethenyl)oxy]-6-hydroxycyclohexa-1,3-diene-1-carboxylic acid, Isochorismate synthase EntC, MAGNESIUM ION | | 著者 | Meneely, K.M, Lamb, A.L. | | 登録日 | 2016-05-16 | | 公開日 | 2016-07-20 | | 最終更新日 | 2024-03-06 | | 実験手法 | X-RAY DIFFRACTION (2.303 Å) | | 主引用文献 | An Open and Shut Case: The Interaction of Magnesium with MST Enzymes.
J.Am.Chem.Soc., 138, 2016
|
|
3HWO
 | |
5O7I
 | | ERK5 in complex with a pyrrole inhibitor | | 分子名称: | 4-(2-bromanyl-6-fluoranyl-phenyl)carbonyl-~{N}-pyridin-3-yl-1~{H}-pyrrole-2-carboxamide, DIMETHYL SULFOXIDE, Mitogen-activated protein kinase 7 | | 著者 | Tucker, J.A, Heptinstall, A, Myers, S. | | 登録日 | 2017-06-08 | | 公開日 | 2018-06-20 | | 最終更新日 | 2024-01-17 | | 実験手法 | X-RAY DIFFRACTION (2.38 Å) | | 主引用文献 | Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38 alpha and BRD4.
Eur.J.Med.Chem., 178, 2019
|
|
